** Alvotech ALVO.O up 5.4% and US shares of Teva Pharmaceuticals TEVA.TA dipping 1.2% on Fri after the partner cos said they launched a biosimilar to Johnson & Johnson's JNJ.N Stelara in the US
** Launch marks the second biosimilar to blockbuster autoimmune drug Stelara following Amgen's AMGN.O Wezlana in Jan, with Biocon Biologics BIOC.NS and Fresenius Kabi FRES.M3 expected to follow soon ** UBS analyst sees launch as a success path for future biosimilars; forecasts global sales of $390 mln by 2028 ** ALVO's stock has fallen about 7% YTD, while TEVA is down 24%
(Reporting by Noel Randewich)
((noel.randewich@tr.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。